SCHEMBL14875464

SCHEMBL14875464

COc1ccc(CNc2nc(SC)ncc2C(=O)Cc2c(Cl)cccc2Cl)cc1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.48
LMNA P02545 2/20 0.44
TP53 P04637 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
POLB P06746 2/20 0.43
JAK3 P52333 1/20 0.42
AURKA O14965 1/20 0.42
RPS6KB1 P23443 1/20 0.42
ABL1 P00519 1/20 0.42
SRC P12931 1/20 0.42
ALDH1A1 P00352 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
VNN1 O95497 2/20 0.41
GAA P10253 1/20 0.40
CCNE2 O96020 1/20 0.40
CCNE1 P24864 1/20 0.40
CDK2 P24941 1/20 0.40
PPARG P37231 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14875800 0.94 MEN1 (0.49) HTTLMNATP53SMN1; SMN2POLB
SCHEMBL14875573 0.87 PPARG (0.45) HTTLMNAJAK3ALDH1A1KMT2A
SCHEMBL16824947 0.85 HTT (0.48) HTTLMNATP53SMN1; SMN2POLB
SCHEMBL14875620 0.83 MAPT (0.43) HTTLMNASMN1; SMN2ALDH1A1MEN1
SCHEMBL16824948 0.82 KDM4E (0.54) HTTPOLBJAK3AURKARPS6KB1
SCHEMBL14875908 0.81 RXFP1 (0.40) HTTLMNASMN1; SMN2JAK3ALDH1A1
SCHEMBL14875738 0.81 RXFP1 (0.43) HTTLMNASMN1; SMN2POLBALDH1A1
SCHEMBL14875793 0.79 LMNA (0.41) HTTLMNASMN1; SMN2ALDH1A1MEN1
SCHEMBL14875821 0.79 ALDH1A1 (0.42) HTTLMNASMN1; SMN2ALDH1A1MEN1
SCHEMBL4712695 0.78 ALDH1A1 (0.65) HTTLMNATP53SMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9181239-B2 Pyridopyrimidinone inhibitors of kinases ABBVIE INC. (US) 2015-11-10 US disclosed
EP-2776434-A1 PYRIDOPYRIMIDINONE INHIBITORS OF KINASES Abbvie Inc. (US) 2014-09-17 EP disclosed
WO-2013059485-A1 PYRIDOPYRIMIDINONE INHIBITORS OF KINASES ABBVIE INC. (US) 2013-04-25 WO disclosed
US-20130102590-A1 PYRIDOPYRIMIDINONE INHIBITORS OF KINASES ABBVIE INC (US) 2013-04-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130102590-A1 PYRIDOPYRIMIDINONE INHIBITORS OF KINASES WEE1, WEE2, CDK1 HTT 4272/4885LMNA 3249/4885TP53 638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.